Prediction of Non-Transplantable Recurrence After Liver Resection for Solitary Hepatocellular Carcinoma

References

• Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–1606. doi:10.1016/j.jhep.2022.08.021
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699. doi:10.1056/NEJM199603143341104
   PubMed Web of Science ®Google Scholar
• Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–1403. doi:10.1053/jhep.2001.24563
   PubMed Web of Science ®Google Scholar
• Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology. 2000;31(4):899–906. doi:10.1053/he.2000.5763
   PubMed Web of Science ®Google Scholar
• Yong CC, Elsarawy AM, Wang SH, et al. The surgical challenges of salvage living donor liver transplantation for Hepatocellular carcinoma; The cumulative experience of 100 cases - A retrospective cohort study and a propensity score analysis. Int J Surg. 2018;54(Pt A):187–192. doi:10.1016/j.ijsu.2018.04.041
   PubMedGoogle Scholar
• Fuks D, Dokmak S, Paradis V, Diouf M, Durand F, Belghiti J. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology. 2012;55(1):132–140. doi:10.1002/hep.24680
   PubMed Web of Science ®Google Scholar
• Tang A, Bashir MR, Corwin MT, et al. Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: a Systematic Review. Radiology. 2018;286(1):29–48. doi:10.1148/radiol.2017170554
   PubMed Web of Science ®Google Scholar
• Chernyak V, Fowler KJ, Kamaya A, et al. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018;289(3):816–830. doi:10.1148/radiol.2018181494
   PubMed Web of Science ®Google Scholar
• American College of Radiology. Liver Imaging Reporting and Data System. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS. Accessed 2 September 2018.
   Google Scholar
• An C, Kim DW, Park YN, Chung YE, Rhee H, Kim MJ. Single Hepatocellular Carcinoma: preoperative MR Imaging to Predict Early Recurrence after Curative Resection. Radiology. 2015;276(2):433–443. doi:10.1148/radiol.15142394
   PubMed Web of Science ®Google Scholar
• Wang L, Feng B, Li D, et al. Risk stratification of solitary hepatocellular carcinoma ≤ 5 cm without microvascular invasion: prognostic values of MR imaging features based on LI-RADS and clinical parameters. Eur Radiol. 2023;33(5):3592–3603. doi:10.1007/s00330-023-09484-5
   PubMed Web of Science ®Google Scholar
• Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143(4):986–994.e983; quiz e914–985. doi:10.1053/j.gastro.2012.05.052
   Web of Science ®Google Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–207. doi:10.1016/S0168-8278(02)00360-4
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jiang H, Chen J, et al. Hepatocellular carcinoma: radiomics nomogram on gadoxetic acid-enhanced MR imaging for early postoperative recurrence prediction. Cancer Imaging. 2019;19(1):22. doi:10.1186/s40644-019-0209-5
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M. -tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Zhang XF, Xue F, Bagante F, et al. Non-transplantable Recurrence After Resection for Transplantable Hepatocellular Carcinoma: implication for Upfront Treatment Choice. J Gastrointest Surg. 2022;26(5):1021–1029. doi:10.1007/s11605-021-05206-8
   PubMed Web of Science ®Google Scholar
• Chow P, Chen M, Cheng A-L, et al. Abstract CT003: iMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. Cancer Res. 2023;83(8_Supplement):CT003–CT003. doi:10.1158/1538-7445.AM2023-CT003
   Google Scholar
• Fernandez-Sevilla E, Allard MA, Selten J, et al. Recurrence of hepatocellular carcinoma after liver transplantation: is there a place for resection? Liver Transpl. 2017;23(4):440–447. doi:10.1002/lt.24742
   PubMed Web of Science ®Google Scholar
• Sposito C, Citterio D, Virdis M, et al. Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma. World J Gastroenterol. 2022;28(34):4929–4942. doi:10.3748/wjg.v28.i34.4929
   PubMed Web of Science ®Google Scholar
• Rhee H, An C, Kim HY, Yoo JE, Park YN, Kim MJ. Hepatocellular Carcinoma with Irregular Rim-Like Arterial Phase Hyperenhancement: more Aggressive Pathologic Features. Liver Cancer. 2019;8(1):24–40. doi:10.1159/000488540
   PubMed Web of Science ®Google Scholar
• Kang TW, Rhim H, Lee J, et al. Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma. Eur Radiol. 2016;26(10):3437–3446. doi:10.1007/s00330-015-4190-5
   PubMed Web of Science ®Google Scholar
• Kierans AS, Leonardou P, Hayashi P, et al. MRI findings of rapidly progressive hepatocellular carcinoma. Magnetic Resonance Imaging. 2010;28(6):790–796. doi:10.1016/j.mri.2010.03.005
   PubMed Web of Science ®Google Scholar
• Kawamura Y, Ikeda K, Hirakawa M, et al. New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma. Hepatology Res. 2010;40(10):1006–1014. doi:10.1111/j.1872-034X.2010.00703.x
   PubMed Web of Science ®Google Scholar
• Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery. Radiology. 2021;300(3):572–582. doi:10.1148/radiol.2021204352
   PubMed Web of Science ®Google Scholar
• Okuda K, Musha H, Nakajima Y, et al. Clinicopathologic features of encapsulated hepatocellular carcinoma: a study of 26 cases. Cancer. 1977;40(3):1240–1245. doi:10.1002/1097-0142(197709)40:3<1240::AID-CNCR2820400339>3.0.CO;2-Y
   PubMed Web of Science ®Google Scholar
• Nagao T, Inoue S, Goto S, et al. Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis. Ann Surg. 1987;205(1):33–40. doi:10.1097/00000658-198701000-00006
   PubMed Web of Science ®Google Scholar
• Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237(4):536–543. doi:10.1097/01.SLA.0000059988.22416.F2
   PubMed Web of Science ®Google Scholar
• Ng IO, Lai EC, Ng MM, Fan ST. Tumor encapsulation in hepatocellular carcinoma. A pathologic study of 189 cases. Cancer. 1992;70(1):45–49. doi:10.1002/1097-0142(19920701)70:1<45::AID-CNCR2820700108>3.0.CO;2-7
   PubMed Web of Science ®Google Scholar
• Ishigami K, Yoshimitsu K, Nishihara Y, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology. 2009;250(2):435–443. doi:10.1148/radiol.2501071702
   PubMed Web of Science ®Google Scholar
• Wang MD, Sun LY, Qian GJ, et al. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: a retrospective cohort study. Int J Surg. 2022;105:106843. doi:10.1016/j.ijsu.2022.106843
   PubMed Web of Science ®Google Scholar
• Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: where Are We? Int J Bio Sci. 2022;18(2):536–551. doi:10.7150/ijbs.64537
   Google Scholar
• Trevisani F, Garuti F, Neri A. Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection. Semin Liver Disease. 2019;39(2):163–177. doi:10.1055/s-0039-1677768
   PubMed Web of Science ®Google Scholar
• Tsilimigras DI, Bagante F, Moris D, et al. Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: a multi-institutional analysis of 1010 patients. Surgery. 2019;166(6):967–974. doi:10.1016/j.surg.2019.08.010
   PubMed Web of Science ®Google Scholar